Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies

By William V. Williams, MD, FACP, CEO, BriaCell Therapeutics Corp.

The biopharmaceutical sector is experiencing a surge of momentum around therapeutic cancer vaccines. Recent clinical data, highlighted by The Wall Street Journal’s report on the latest wave of mRNA cancer vaccine trials, has reinvigorated industry enthusiasm. By leveraging personalized neoantigen profiles in adjuvant settings, these approaches are proving that the immune system can be trained to recognize tumor-specific mutations and reduce the risk of disease recurrence.

This news is an encouraging validation for the entire immuno-oncology field. Yet applying these advancements to late-stage solid cancers, which account for a high proportion of cancer modalities, presents significant biological and logistical challenges. Neoantigen vaccines represent only one piece of a complex puzzle. Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.

The Solid Tumor Bottleneck

Checkpoint inhibitors proved that releasing the immune system’s natural "brakes" could yield durable responses. Yet single-agent therapies and narrow-target vaccines frequently run into severe resistance mechanisms, particularly in immunologically "cold" solid tumors where there is no preexisting immune response, such as metastatic breast, prostate, and pancreatic cancers.

Solid tumors actively construct immunosuppressive microenvironments. They downregulate major histocompatibility complex (MHC) molecules, secrete inhibitory cytokines, and build physical barriers that block immune infiltration. Furthermore, because solid tumors exhibit high intratumoral heterogeneity and mutate rapidly, single-target monotherapies often select for immune-evading clone populations.

To overcome these escape mechanisms, early-stage research must look past single-pathway strategies and engineer preclinical platforms designed for comprehensive immune activation and long-term scalability.

Priority 1: Engineering Multiple Immune Activation (CD4+ And CD8+, NK, NKT, And Dendritic Cells)

A critical focus in modern preclinical development is the simultaneous engagement of both helper (CD4+) and cytotoxic (CD8+) T cells. Many early-stage vaccine strategies focus predominantly on mounting a CD8+ cytotoxic T-cell attack. While CD8+ T cells serve as primary effectors that directly destroy malignant cells, they rapidly become exhausted within the hostile solid tumor microenvironment without sustained helper signals.

Preclinical models demonstrate that dual immune stimulation produces a far more potent and durable anti-tumor response. Platforms engineered to present multiple tumor targets while simultaneously utilizing immune-stimulating cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), effectively recruit and activate native antigen-presenting cells. This dual mechanism primes CD4+ T cells to orchestrate the immune response and support CD8+ T cells in penetrating cold tumors, transforming immunologically quiet environments into targets vulnerable to immune attack.

Activating other arms in the immune system can also be beneficial. The innate immune system includes natural killer (NK) cells, NKT cells, and dendritic cells. NK and NKT cells are directly cytotoxic to tumors and use a different recognition system than CD4+ and CD8+ cells. Dendritic cells can initiate an immune response and activate naïve T cells. Thus, multiple arms of the immune system can be brought to bear on the cancer cells.

Priority 2: Countering Antigenic Drift And Immune Evasion With Multitarget Platforms

The limits of monotherapy are well documented. When a treatment targets a single antigen, the tumor often adapts via antigenic drift, shedding that target and continuing to proliferate.

To mitigate this risk during discovery, drug developers are increasingly designing off-the-shelf whole-cell platforms and poly-antigen strategies. By presenting a broad spectrum of tumor-associated antigens directly to the host immune system, these multitargeted platforms induce a polyclonal immune response. Attacking multiple biological pathways at once raises the barrier for tumor resistance, reducing the likelihood that mutated sub-clones will escape immune surveillance.

Another form of immune escape is the down regulation of human leukocyte antigen (HLA) molecules, also known as immune evasion. These are the molecules that present antigens to T cells, and some cancers will delete these molecules and thus escape immune detection. Fortunately, NK and NKT cells specifically target cells that lack HLA molecules and therefore can limit the ability of cancers to escape immune detection by this mechanism.

Priority 3: Designing For Off-The-Shelf Scalability At Inception

Commercial and logistical viability must be integrated into drug discovery long before a candidate enters clinical testing. While autologous therapies, such as first-generation CAR-T or custom mRNA vaccines, offer high personalization, they carry significant logistical burdens. Harvesting individual patient tissue, custom manufacturing a therapy, and shipping it back creates long turnaround times and steep costs that put enormous strain on healthcare systems.

For patients with rapidly progressing, heavily pretreated solid tumors, waiting weeks for custom manufacturing is often not a viable option.

Off-the-shelf strategies solve this bottleneck by utilizing premanufactured standardized cell lines. When platforms are designed around standard tissue-type profiling, such as simple HLA matching, physicians can match patients and initiate targeted treatment immediately upon progression. Establishing off-the-shelf cell banking models during early preclinical development lowers long-term manufacturing overhead, streamlines regulatory translation, and ensures that breakthroughs can actually reach broad patient populations.

A Comprehensive Path Forward

The recent wave of positive news around mRNA cancer vaccines highlights the tremendous potential of cancer immunotherapies. Yet, as the oncology community looks toward difficult-to-treat solid tumors, success will rely on a multipronged strategy.

By designing preclinical platforms that combine multitarget antigen presentation, multiple immune stimulation, and off-the-shelf scalability, the biopharmaceutical sector can move beyond single-pathway innovation. Aligning early-stage biology with real-world clinical and manufacturing realities will ensure that the next generation of immuno-oncology delivers durable, accessible care to patients who need it most.

About The Author

William V. Williams, MD, FACP, president and CEO of BriaCell Therapeutics Corp., is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies.

Williams earned his BS in chemistry and biotechnology from MIT and his MD from Tufts University School of Medicine. At the University of Pennsylvania, he developed novel methods of bioactive peptide design, ran a major research program in receptor biology, and collaborated in the development of DNA vaccines. At GlaxoSmithKline, he brought several molecules into the clinic, ran an international biomarker laboratory, and worked on regulatory approvals for drugs. At Incyte Corporation, he established proof of concept for drugs in several disease areas including cancer, rheumatoid arthritis, psoriasis, and diabetes.